ProQR Therapeutics N.V (NASDAQ:PRQR)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 0.28. At the close of trading, the stock’s price was $2.37, to imply an increase of 3.04% or $0.07 in intraday trading. The PRQR share’s 52-week high remains $4.62, putting it -94.94% down since that peak but still an impressive 32.07% since price per share fell to its 52-week low of $1.61. The company has a valuation of $244.59M, with an average of 0.31 million shares in intraday trading volume over the past 10 days and average of 771.64K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for ProQR Therapeutics N.V (PRQR), translating to a mean rating of 1.29. Of 5 analyst(s) looking at the stock, 0 analyst(s) give PRQR a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.15.
ProQR Therapeutics N.V (NASDAQ:PRQR) trade information
After registering a 3.04% upside in the last session, ProQR Therapeutics N.V (PRQR) has traded red over the past five days. The 5-day price performance for the stock is -2.07%, and -4.05% over 30 days. With these gigs, the year-to-date price performance is -10.57%. Short interest in ProQR Therapeutics N.V (NASDAQ:PRQR) saw shorts transact 0.92 million shares and set a 1.56 days time to cover.
The extremes give us $2 and $5 for target low and target high price respectively. As such, PRQR has been trading -110.97% off suggested target high and 15.61% from its likely low.
ProQR Therapeutics N.V (PRQR) estimates and forecasts
Looking at statistics comparing ProQR Therapeutics N.V share performance against respective industry, we note that the company has outperformed competitors. ProQR Therapeutics N.V (PRQR) shares are 31.67% up over the last 6 months, with its year-to-date growth rate higher than industry average at 18.42% against 16.60%. The rating firms project that company’s revenue will grow 112.72% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 6.39M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 8.99M.Earnings reports from the last fiscal year show that sales brought in 6.79M and 5.02M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -5.82% before jumping 79.06% in the following quarter.
PRQR Dividends
ProQR Therapeutics N.V has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is ADAGE CAPITAL PARTNERS GP, L.L.C. with 3.63 million shares, or about 4.4446% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $6.02 million.
We also have Delaware Group Equity Fds IV-Delaware Healthcare Fund and Fidelity Small Cap Growth Fund as the top two Mutual Funds with the largest holdings of the ProQR Therapeutics N.V (PRQR) shares. Going by data provided on Sep 30, 2024 , Delaware Group Equity Fds IV-Delaware Healthcare Fund holds roughly 620.0 shares. This is just over 0.76% of the total shares, with a market valuation of $1.47 million. Data from the same date shows that the other fund manager holds a little less at 600.19, or 0.73% of the shares, all valued at about 1.42 million.
